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Rhus verniciflua Stokes (RVS) and butein
induce apoptosis of paclitaxel-resistant
SKOV-3/PAX ovarian cancer cells through
inhibition of AKT phosphorylation
Hyeong Sim Choi1, Min Kyoung Kim1, Youn Kyung Choi2,3, Yong Cheol Shin3, Sung-Gook Cho4*
and Seong-Gyu Ko3*
Abstract
Background: Rhus verniciflua Stokes (RVS) belongs to the Anacardiaceae family and traditionally used for cancer
treatment. RVS and butein, a major compound of RVS, were known to induce apoptosis via AKT inhibition in cancer
cells. Thus, in this study, we investigated the effect of RVS and its derivative compounds (fisetin, quercetin, butein)
on cell death in SKOV-3/PAX cells.
Methods: The 80 % ethanol extract of RVS and its derivative compounds (fisetin, quercetin, butein) were prepared.
The cytotoxicity was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric
assay. Apoptotic cells were detected by staining with propidium iodide (PI) and Annexin V-fluorescein isothiocyanate/
7-aminoactinomycin D (Annexin V-FITC/7-AAD). The expression level of intracellular signaling related-proteins in
apoptosis and growth were measured by western blot assay.
Results: We found that RVS and butein suppressed the growth of SKOV-3/PAX cells in a dose-dependent manner.
We also found that RVS and butein produced the cleavage of caspase-9, -8, -3, and PARP. Similarly, sub-G1 phase and
Annexin V-FITC positive cells were increased by RVS and butein. Moreover, RVS and butein significantly reduced AKT
phosphorylation in SKOV-3/PAX cells. PI3K inhibitor LY294002 caused PARP cleavage supporting our finding.
Conclusion: Our data clearly indicate that RVS and butein induce apoptosis of SKOV-3/PAX cells through inhibition of
AKT activation. RVS and butein could be useful compounds for the treatment for paclitaxel resistant-ovarian cancer.
Keywords: Rhus verniciflua Stokes, Butein, AKT, Paclitaxel-resistant ovarian cancer, Apoptosis
Background
Cancer is one of disease and is the second leading cause
of death all over the world [1, 2]. Although the incidence
of ovarian cancer is the eighth in developed and devel-
oping countries in women. However, the mortality rate
for ovarian cancer is the fifth and higher in more devel-
oped countries than less developed countries. Further
reductions in cancer death rates can be improved by
applying various therapies including surgery, radiation
chemotherapy, hormonal therapy, and chemotherapy [3].
One of the most common chemotherapy agent used
for the treatment of ovarian cancer patients are taxanes,
such as paclitaxel [4, 5]. Despite many studies on ther-
apy for decades, there are still considerable problems to
be solved such as multi-drug resistant (MDR) [6, 7].
MDR plays a key role in chemotherapy because of exist-
ing anti-cancer drugs effectiveness wearing of as tumor
build tolerance to them. Although ovarian cancer is sen-
sitive to paclitaxel in early days, tumors ultimately are
not in patients because of MDR [8, 9]. One of the acqui-
sition mechanisms to paclitaxel is known as activation of
the AKT [10, 11]. Phosphorylated AKT (p-AKT) is lead
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to an increase in cell growth but it inhibits cell death
[12, 13]. Accordingly, the combination of AKT inhibitors
with chemotherapy agent has been shown to sensitize
ovarian cancer patients [14, 15].
Rhus verniciflua Stokes (RVS) has many useful effects
such as it loosen the extravasated blood in the liver, con-
trol inflammation, and help the digestive organs in
Donguibogam or a botanical list. Moreover, RVS is docu-
mented to be used for treating various diseases such as
obesity, allergic inflammatory, allergic contact dermatitis,
swelling, angiogenesis, Parkinson’s disease, Huntington’s
disease, and cancer [16–18]. RVS is composed of diverse
compounds such as butein, fisetin and quercetin [19].
Previous studies have demonstrated that RVS and
butein induce cell death via AKT pathway in cancer cells
[20, 21]. However, it is not reported that RVS or butein
is lead to cell death through blocking AKT activation in
paclitaxel-resistant ovarian cancer cells. In this study, we
wanted to know that whether RVS of ethanol extracted
can be induced apoptosis in paclitaxel resistant ovarian
cancer. We have shown that RVS was inhibited AKT-
mediated proliferation via inducing apoptosis. Moreover,
butein, a compound of RVS, showed the same results as
the RVS. Therefore, our results indicate that RVS and




Toxicodendron vernicifluum Stokes, formerly known as
Rhus verniciflua Stokes (RVS) and the common name is
Chinese lacquer tree. RVS belongs to the Anacardiaceae
family and deciduous tree species [19, 22]. It is about 10
~ 20 meter in height and divided into yellow endothelial
and gray outer. The purpose of its cultivation is mainly
used to paint with lacquer collected the sap or get wax
from the fruit. Before you use it for food or medicine, it
should be removed completely toxic due to the poison-
ous of RVS [23].
Preparation of RVS extracts and chemical compounds
80 % ethanol extract of RVS used in this research was
provided from Hanpoong pharm (Jeonju, Republic of
Korea). The powder form of RVS was dissolved in 30 %
ethanol to make a stock solution and stored at -80 °C
until ready for use. Fisetin (PubChem CID: 5281614)
and quercetin (PubChem CID: 5280343) were purchased
from Sigma (St. Louis, MO). Butein (PubChem CID:
5281222) was obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA).
Cell lines and cell culture
The paclitaxel resistant ovarian cancer cells, SKOV-3/
PAX cells were provided by Prof. Cho. These cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10 % heat-inactivated fetal bovine
serum (FBS), 1 % antibiotic-antimycotic solution, and
5nM of paclitaxel in a humidified atmosphere of 5 %
CO2 at 37 °C.
Cell proliferation assay
For cell proliferation assay, SKOV-3 or SKOV-3/PAX
were seeded at 5x103 cells in 96 well plates and then
treated with paclitaxel (0, 1,10, 100 and 1000nM), RVS
(0, 50, 100, 200 and 500 μg/mL), or butein (0, 2.5, 5 and
10 μg/mL) for 72 hours. Thereafter, cell viability was
performed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) colorimetric assay with an
absorbance at 570 nm.
FACS analysis
Dead cells were measured by propidium iodide (PI)
staining because PI is bound to DNA and can be used to
detect abnormal cell populations. SKOV-3/PAX cells
were treated with RVS and butein for 24 hours, and then
fixed 70 % ethanol in ice-cold PBS at -20 °C. Next day,
the fixed cells were resuspended in PBS containing 50 μg/
mL of PI and 50 μg/mL of RNAse A, and incubated in the
dark for 15 minutes at room temperature. The DNA con-
tents of samples were analyzed by FACSCalibur flow cyt-
ometer (Becton-Dickinson, San Jose, CA). Apoptotic dead
cells were detected by Annexin V-fluorescein isothiocyan-
ate (FITC) and 7-aminoactinomycin D (7-AAD) staining.
Annexin V-FITC, staining for phosphatidylserine (PS) in
cell membrane, is detected in early apoptosis. 7-AAD is a
membrane impermeability dye that is generally stained
apoptotic cells and excluded viable cells. SKOV-3/PAX
cells were treated with RVS and butein, and then har-
vested in Annexin V binding buffer. The samples were
stained with Annexin V-FITC in the dark for 15 minutes
at room temperature and gave more staining with 7-AAD
in the same way. 2-dimensional staining to measure apop-
tosis and necrosis was subjected to FACSCalibur.
Western blot
Whole lysates, proteins extracted from SKOV-3/PAX
were separated by 10-15 % SDS-PAGE according to their
molecular weights. Each protein was transferred to
nitrocellulose blotting membrane and blotted by appro-
priate antibodies for following molecules at 4 °C; Anti-
cleaved caspase-9 (sc22182), -p-p38 (sc7973), -p-JNK
(sc6254), -ERK (sc1647), and -p-ERK (sc7383) antibodies
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Anti-cleaved caspase-8 (#9496), -cleaved
caspase-3 (#9661), -PARP (#9542), -p-Raf-1 (#9421),
-AKT (#9272), -p-AKT (S473) (#9271), -JNK (#3708), and
-p38 (#9212) antibodies were obtained from Cell Signaling
Technology (Danver, MA, USA). Anti-α-tubulin (T5168)
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antibody was purchased from Sigma (St. Louis, MO). Next
day, the membranes were washed three times in phos-
phate buffered saline with 0.01 % tween-20 (PBST) and in-
cubated at room temperature for 1 hour with secondary
antibodies. The membranes were then washed with PBST
three times and visualized the protein bands using an en-
hanced chemiluminescence detection system (DoGen-Bio,
Seoul, Korea) and exposed to X-ray film (Agfa-Gevaert
N.V., Mortsel, Belgium).
Statistical analysis
All experimental data were shown as mean ± SD and ana-
lyzed by Student t-test using Microsoft excel software.
P value less than 0.05 was considered statistically significant.
Results
RVS inhibits cell proliferation in chemoresistant SKOV-3 cells
We first examined that whether SKOV-3/PAX cells were
acquired resistant to paclitaxel from parental cells. As
shown in Fig. 1a, paclitaxel inhibited growth of SKOV-3
cells, but not in SKOV-3/PAX cells. Next, we treated
with RVS to identify the anti-proliferation effects in
paclitaxel-resistant cells. As shown in Fig. 1b, RVS sup-
pressed in a-dose dependently cell growth in SKOV-3/
PAX cells. Therefore, our results indicate that RVS ef-
fectively inhibits the proliferation of paclitaxel-resistant
ovarian cancer cells.
RVS induces apoptosis in paclitaxel-resistant ovarian
cancer cells
To determine whether RVS could induce the cell death
in SKOV-3/PAX cells, we were treated at various con-
centrations of RVS. First, we were stained DNA by PI
and detected dead cells. The sub-G1 phases, dead cells,
were increased by RVS in a dose-dependently manner.
Especially, dead cell population showed that 500 μg/ml
of RVS induced the sub-G1 phase to 20.4 % compared
with control (Fig. 2a). Next, in order to whether RVS in-
duces cell death inducing apoptosis or necrosis, we per-
formed Annexin V-FITC and 7-AAD staining. SKOV-3/
PAX cells were stained with Annexin V-FITC and 7-AAD,
and then measured the proportion of apoptosis and
necrosis-related cell death (Fig. 2b). As a result, it was
increased the cell death due to apoptosis more than ne-
crosis. Lastly, we were observed the change of apoptosis-
related proteins. Cleaved form of PARP, caspase-9, -8, and
-3 were increased by RVS treatment in SKOV-3/PAX cells
(Fig. 2c). Therefore, our data show that RVS induces
apoptosis through the caspase-dependent pathway.
Butein suppresses cell proliferation and enhances
apoptosis in paclitaxel-resistant ovarian cancer cells
We also wanted to know that whether which com-
pounds of RVS was induced cell death in paclitaxel re-
sistant ovarian cancer cells. As shown in Fig. 3a, butein
significantly reduced cell growth than other compounds
of RVS, such as fisetin or quercetin. It is reported that
fisetin induces apoptosis in human non-small cell lung
cancer via inhibiting MAPK signaling pathway and quer-
cetin increases the apoptosis rate of ovarian cancer cells
[24, 25]. To confirm whether butein caused apoptotic
cell death, we treated with butein on SKOV-3/PAX cells.
Like RVS, butein dose-dependently increased sub-G1
phase (Fig. 3b) and induced the apoptotic-cell death
(Fig. 3c). Moreover, butein increased levels of activated
caspase-9, -8, -3, and cleaved PARP in SKOV-3/PAX
cells (Fig. 3d). Therefore, our data demonstrate that
butein is the active compound of RVS and contributes
to paclitaxel-resistant ovarian cancer cell apoptosis via
caspase-dependent signaling.
RVS and butein disrupt cell growth via AKT pathway in
paclitaxel-resistant ovarian cancer cells
Further our understanding of the molecular effect of
























































Fig. 1 Proliferation of parental and paclitaxel resistant ovarian cancer
cells by paclitaxel or RVS treatment for 72 hours. a The effect of
paclitaxel on the viability in SKOV-3 or SKOV-3/PAX cells was determined
by MTT assay. b The effect of RVS on the viability in SKOV-3/PAX cells
was determined by MTT assay (mean ± SD; n = 6). *, p < 0.05 versus
control in parental. **, p < 0.05 versus control in resistant
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were treated with RVS or butein for 24 hours. When
SKOV-3/PAX cells were treated with RVS, phosphor-
ylation of AKT were reduced in a time-dependently
manner (Fig. 4a). But phosphorylation of ERK was in-
duces by RVS. In the case of butein, phosphorylation
of ERK and p38 were decreased as well as AKT activ-
ity (Fig. 4b). Our data showed that inhibition of AKT
activity was decreased by both RVS and butein, also
the AKT signaling pathway is well known as a key
role in cancer cell growth. Therefore, we showed that
inhibition of AKT phosphorylation using by AKT
inhibitor, LY294002, the PARP cleaved was increased
by as much as RVS and butein (Fig. 4c). These results
demonstrated that RVS and butein are inducing apop-
tosis through AKT signaling pathway (Fig. 4d).
Discussion
Numerous reports are shown that AKT phosphoryl-
ation is induced in ovarian cancer patients and
paclitaxel-treated in ovarian carcinoma cells. Induc-
tion of AKT activation causes tumorigenesis and be-
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Fig. 2 RVS induces apoptotic-cell death in paclitaxel resistant ovarian cancer cells for 24 hours. a Left panel, the cytotoxic effect of RVS in SKOV-3/PAX
cells was determined by PI staining assay. Right panel, data represent quantitative results for left panel (mean ± SD; n = 3). *, p < 0.05. b The dead cells
were differentiated between apoptosis and necrosis by Annexin V-FITC and 7-AAD dual staining. c The expression of procaspase-9, cleaved caspase-9,
cleaved caspase-8, procaspase-3, caspase-3, and PARP in cell lysates from SKOV-3/PAX cells treated with RVS was determined by Western blot assay
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be treated together inhibiting of AKT activity as well
as increasing apoptosis [28, 29]. Recent studies
showed that RVS reduces AKT phosphorylation in
gastric cancer cell lines [30] and that n-butanol ex-
tract form RVS decreases LPS-induced AKT activation
in macrophage RAW 264.7 cells [31]. Therefore, we
evaluated the effects of RVS in paclitaxel-resistant
ovarian cancer cell lines.
The results indicate that RVS was lead to apoptosis
via both accumulation of cleaved PARP form and sup-
pression of AKT activation in a dose-dependent man-
ner. Furthermore, we conducted experiments to know
what compounds of RVS have these capabilities.
Among the three compounds, butein effected best,
reducing the proliferation of SKOV-3/PAX cells.
Butein, a bioactive flavonoid [32, 33], was effective for
cancer treatment through apoptosis pathway such as
caspases and PARP. Also, Butein affected the cell pro-
liferation via repressing AKT phosphorylation in cer-
vical cancer cells and AKT-dependent phosphorylation
of hTERT in leukemia cells [32, 34]. It is reported that
other compounds, fisetin and quercetin, induce apop-
tosis in cancer cells, but slightly inhibited proliferation
in SKOV-3/PAX cells [24, 25]. Lastly, after treatment
of SKOV-3/PAX cells with PI3K inhibitor LY294002,
the function of AKT was repressed. The result is RVS
and butein can induce SKOV-3/PAX cell apoptosis by










































































sub-G1: 2.9 % sub-G1: 7.5 %
sub-G1: 12.4 % sub-G1: 10.4 %
2.50 Butein (µg/ml)
Fig. 3 The effect of apoptosis in butein-treated SKOV-3/PAX cells. (a) The effect of butein, fisetin, and quercetin on the viability in SKOV-3/PAX
cells for 72 hours was determined by MTT assay. (b) The cytotoxic effect of butein in SKOV-3/PAX cells for 24 hours was determined by PI staining
assay. Bottom panel, data represent quantitative results for top panel (mean ± SD; n = 3). *, p < 0.05 versus control. (c) The dead cells were differentiated
between apoptosis and necrosis by Annexin V- FITC and 7-AAD dual staining. (d) The expression of procaspase-9, cleaved caspased-9,
cleaved caspase-8, procaspase-3, caspase-3, and PARP in cell lysates from SKOV-3/PAX cells treated with butein were determined by Western blot assay
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present study suggested that the inhibiting AKT phos-
phorylation is a key role for the apoptosis of paclitaxel-
resistant ovarian cancer cells.
Conclusion
We show that RVS and its active compound, butein,
may enhance apoptosis and reduce proliferation through
the inhibition of AKT activation in paclitaxel resistant-
ovarian cancer. Therefore, our results suggested that
RVS could be useful for the chemotherapy of drug-
resistant cancer and more researches are needed to fur-
ther a detailed mechanism.
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Apoptosis of SKOV-3/PAX cells
Butein in RVS
Fig. 4 RVS and butein inhibit AKT signaling in SKOV-3/PAX cells for 2 hours. (a and b) The expression of AKT, Raf-1, ERK, p38, and JNK in cell
lysates from SKOV-3/PAX cells treated with RVS or butein were determined by Western blot assay. (c) SKOV-3/PAX cells were pretreated with
AKT inhibitor, LY294002 (50 μM) for 1 hour and then added with RVS or butein for another 24 hours. The expression levels of AKT phosphorylation and
PARP cleavage were determined by Western blot assay. (d) A schematic model for the apoptosis via inhibition of AKT activity by RVS or butein
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